Latest News on ZVRA

Financial News Based On Company


Advertisement
Advertisement

Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

https://www.globenewswire.com/news-release/2026/11/18/3405544/16626/en/zevra-therapeutics-to-present-at-the-piper-sandler-annual-healthcare-conference.html
Zevra Therapeutics announced that its executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, in New York, NY. The company, focused on life-changing therapeutics for rare diseases, will also be available for one-on-one meetings with registered attendees. A live webcast of the presentation will be available on Zevra's investor relations website.

Zevra Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

https://pluang.com/en/news-feed/zevra-therapeutics-memenuhi-konferensi-kesehatan-piper-sandler-2026
Zevra Therapeutics announced that its executive team will present at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, in New York. The company, which specializes in rare disease therapies, will also host one-on-one meetings to highlight its pipeline progress and commitment to innovative treatments. This event underscores Zevra's efforts to expand access to its therapies, including its lead product for Niemann-Pick disease type C.

Zevra Therapeutics to Present at Piper Sandler 38th Annual Healthcare Conference

https://www.quiverquant.com/news/Zevra+Therapeutics+to+Present+at+Piper+Sandler+38th+Annual+Healthcare+Conference%0A
Zevra Therapeutics announced its executive leadership will present at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 1:00 p.m. ET, offering one-on-one meetings. The company, focused on rare diseases and successful with its Niemann-Pick disease type C product, aims to expand access and advance its late-stage pipeline. The announcement also includes details on ZVRA's insider trading, revenue, hedge fund activity, and recent analyst ratings.

Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

https://finance.yahoo.com/healthcare/articles/zevra-therapeutics-present-piper-sandler-123000951.html
Zevra Therapeutics announced that its executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 1:00 p.m. ET. Management will also be available for one-on-one meetings, and a live webcast link will be provided on the company's investor relations website. Zevra Therapeutics is a commercial-stage company focused on developing and delivering life-changing therapeutics for people with rare diseases, with a lead product for Niemann-Pick disease type C already commercialized in the U.S.

Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $18 at Guggenheim

https://www.streetinsider.com/Analyst+Comments/Zevra+Therapeutics%2C+Inc.+%28ZVRA%29+PT+Lowered+to+%2418+at+Guggenheim/27348583.html
Guggenheim analyst Eddie Hickman lowered the price target for Zevra Therapeutics (ZVRA) to $18 from $23, while maintaining a Buy rating. This adjustment follows the EMA's refusal of the Meplyffa (arimoclomol) MAA in NPC after re-examination, prompting the removal of the EU opportunity from Guggenheim's model. The analyst views U.S. Miplyffa sales and FDA feedback on celiprolol as key upcoming focuses and catalysts for investors.
Advertisement

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

https://finance.yahoo.com/healthcare/articles/zevra-therapeutics-announces-final-chmp-112600453.html
Zevra Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the Marketing Authorization Application (MAA) for arimoclomol for treating Niemann-Pick disease type C (NPC) in the EU. Despite this, Zevra will continue its global Expanded Access Program for eligible patients and remains committed to supporting the NPC community, believing the data package demonstrated arimoclomol's therapeutic benefit. The European Commission is expected to issue its final decision within 67 days.

BTIG maintains Zevra Therapeutics at Buy, lowers price target to $21 from $24

https://www.tradingview.com/news/tradingview:29c871b477356:0-btig-maintains-zevra-therapeutics-at-buy-lowers-price-target-to-21-from-24/
BTIG has reiterated its "Buy" rating for Zevra Therapeutics (ZVRA) but has decreased its price target from $24 to $21. This new price target suggests an 88.2% upside from the stock's closing price of $11.16 on November 12.

A European panel gives Zevra's rare-disease drug application a negative opinion; EU decision is expected in 67 days.

https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-announces-final-chmp-opinion-on-arimoclomol-for-nuq9pzh5j225.html
Zevra Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on its Marketing Authorization Application (MAA) for arimoclomol, a drug for Niemann-Pick disease type C (NPC). Despite this, Zevra will continue supporting eligible patients through its global Expanded Access Program. The European Commission is expected to make its final decision within 67 days.

Zevra Shares Fall As EU Panel Issues Negative Opinion On Arimoclomol

https://www.rttnews.com/3714547/zevra-shares-fall-as-eu-panel-issues-negative-opinion-on-arimoclomol.aspx
Zevra Therapeutics' shares fell after the European Medicines Agency's CHMP adopted a negative opinion on its application for arimoclomol to treat Neimann-Pick disease type C (NPC). Despite the setback, the company plans to continue providing arimoclomol through its Expanded Access Program, pending regulatory approval. The European Commission is expected to make a final decision within 67 days, while ZVRA stock experienced a pre-market decline.

EU committee issues negative opinion on Zevra's arimoclomol for Niemann-Pick disease treatment

https://pluang.com/en/news-feed/zevra-therapeutics-opini-negatif-chmp-arimoclomol-npc-eu
The European Medicines Agency's CHMP has issued a negative opinion regarding Zevra Therapeutics' arimoclomol for treating Niemann-Pick disease type C, a rare neurodegenerative disorder. Despite clinical trial data showing reduced disease progression, the European Commission will make the final decision within 67 days. Zevra plans to continue supporting existing patients through its Expanded Access Program, marking this as a setback for patients in Europe awaiting new treatment options.
Advertisement

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

https://www.manilatimes.net/2026/11/13/tmt-newswire/globenewswire/zevra-therapeutics-announces-final-chmp-opinion-on-arimoclomol-for-the-treatment-of-niemann-pick-disease-type-c-npc-in-the-european-union/2469459
Zevra Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the Marketing Authorization Application for arimoclomol, a treatment for Niemann-Pick disease type C (NPC). Despite this setback, Zevra remains committed to supporting eligible patients through its global Expanded Access Program and believes in the therapeutic benefit of arimoclomol, citing robust clinical and real-world data. The NPC community, represented by the International Niemann-Pick Disease Alliance, expressed deep disappointment but remains dedicated to advocating for affected individuals and their families.

Zevra gets negative EU opinion for rare disease drug

https://www.investing.com/news/company-news/zevra-gets-negative-eu-opinion-for-rare-disease-drug-93CH-5024875
Zevra Therapeutics Inc. (NASDAQ:ZVRA) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its Marketing Authorization Application for arimoclomol, a drug intended to treat Niemann-Pick disease type C. This rare neurodegenerative disorder affects approximately 1,000 people in Europe, and despite clinical trial data showing the drug reduced disease progression, the CHMP's decision has been met with disappointment by the company and patient advocacy groups. Zevra will continue its Expanded Access Program for eligible patients.

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

https://www.globenewswire.com/news-release/2026/11/13/3402453/16626/en/zevra-therapeutics-announces-final-chmp-opinion-on-arimoclomol-for-the-treatment-of-niemann-pick-disease-type-c-npc-in-the-european-union.html
Zevra Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the Marketing Authorization Application for arimoclomol for Niemann-Pick disease type C (NPC). Despite this setback, Zevra will continue to support eligible patients through its global Expanded Access Program. The company expressed deep disappointment, highlighting the significant unmet medical need for NPC patients and their families.

Zevra Therapeutics, Inc. (ZVRA) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ZVRA/seasonality/
This Yahoo Finance article presents a seasonal returns chart for Zevra Therapeutics, Inc. (ZVRA), showing the average monthly price return from 2016 to 2026. The stock's current real-time price and recent trading activity, including an overnight session on the Blue Ocean ATS, are also provided.

Zevra Therapeutics, Inc. (ZVRA) Seasonal returns chart

https://au.finance.yahoo.com/quote/ZVRA/seasonality/
The article provides a snapshot of Zevra Therapeutics, Inc. (ZVRA) stock information, including its real-time price, recent performance, and a note that seasonality data is currently unavailable. It shows the stock trading at $11.59, up 10.07% at close, with slight overnight activity.
Advertisement

Zevra Therapeutics, Inc. Just Beat EPS By 69%: Here's What Analysts Think Will Happen Next

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/zevra-therapeutics-inc-just-beat-eps-by-69-heres-what-analys
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) recently announced its latest quarterly results, with shares rising 2.4% to US$10.53. The company reported revenues of US$38m, meeting analyst expectations, but surprised with a statutory profit of US$0.26 per share, which was 69% above forecasts. Analysts have largely reconfirmed their future estimates, expecting revenues of US$176.5m in 2027 and EPS to decrease by 29% to US$0.90, maintaining a consensus price target of US$25.25.

Fidelity Contrafund holds 5.6% of Zevra (ZVRA); FMR also reports a stake.

https://www.stocktitan.net/sec-filings/ZVRA/schedule-13g-a-zevra-therapeutics-inc-amended-passive-investment-disc-1396cd73b2d5.html
FMR LLC reported a 9.4% beneficial ownership in Zevra Therapeutics (ZVRA), totaling 5,562,781 shares of common stock as of September 30, 2026. Within this, Fidelity Contrafund held an interest of 3,317,068 shares, which accounts for 5.6% of ZVRA's outstanding common stock. The report details sole voting power for FMR LLC over 5,548,994 shares, while Abigail P. Johnson reported zero sole voting power.

Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...

https://sg.finance.yahoo.com/news/zevra-therapeutics-inc-zvra-q3-071022863.html
Zevra Therapeutics Inc reported a significant 45% year-over-year increase in total net revenue to $37.8 million for Q3 2026, driven by strong MIPLYFFA sales. The company maintains a robust financial position with $270.9 million in cash and investments and plans to expand MIPLYFFA's label for infants under 24 months. Despite challenges like regulatory uncertainty for arimoclomol and slow enrollment in the DiSCOVER trial, Zevra is confident in its market position and growth strategy for Niemann-Pick disease type C.

Zevra Therapeutics earnings beat by $0.10, revenue topped estimates

https://www.investing.com/news/earnings/zevra-therapeutics-earnings-beat-by-010-revenue-topped-estimates-4996675
Zevra Therapeutics (NASDAQ: ZVRA) reported strong third-quarter results, beating analyst estimates with an EPS of $0.260 against a projected $0.160. The company also exceeded revenue expectations, bringing in $37.8M compared to the consensus estimate of $37.08M. Despite these positive results, the stock has seen a decline of 11.250% over the last three months, though it is up 4.800% over the last year.

Form 8K Zevra Therapeutics Inc For: 3 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-zevra-therapeutics-inc-for-3-november-93CH-5676219
Investing.com reported that Zevra Therapeutics Inc. filed a Form 8K on November 3. The article is a brief announcement indicating the regulatory filing, without providing further details about the content of the 8K. It also lists the stock symbol ZVRA with a recorded gain of 1.58%.
Advertisement

Zevra Therapeutics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:80c6dfbe2094b:0-zevra-therapeutics-q3-earnings-call-highlights/
Zevra Therapeutics reported strong third-quarter 2026 results, with net revenue up 45% to $37.8 million, driven by U.S. sales of MIPLYFFA for Niemann-Pick disease type C (NPC). The company also achieved a net income of $19.2 million and continues to expand MIPLYFFA's market reach, pursue label expansion for pediatric patients, and advance its celiprolol program for vascular Ehlers-Danlos syndrome. Zevra maintains a solid financial position with $270.9 million in cash and investments.

Zevra Therapeutics, Inc. (ZVRA) Tops Q3 EPS by 10c

https://www.streetinsider.com/Earnings/Zevra+Therapeutics%2C+Inc.+%28ZVRA%29+Tops+Q3+EPS+by+10c/27283114.html
Zevra Therapeutics, Inc. (ZVRA) announced its Q3 earnings, reporting an EPS of $0.26, which surpassed analyst estimates by $0.10. The company's revenue for the quarter also exceeded expectations, coming in at $37.8 million against a consensus estimate of $37.08 million.

Zevra Reports Third Quarter 2026 Financial Results and Corporate Update

https://www.globenewswire.com/news-release/2026/11/03/3394772/16626/en/zevra-reports-third-quarter-2026-financial-results-and-corporate-update.html
Zevra Therapeutics announced strong third-quarter 2026 financial results, reporting $37.8 million in net revenue, a 45% increase over Q3 2025, primarily driven by $34.0 million from MIPLYFFA sales. The company also highlighted progress in its pipeline, including advancing celiprolol for Vascular Ehlers-Danlos Syndrome and pursuing European access for arimoclomol, while maintaining a strong cash position of $270.9 million. Zevra anticipates filing a supplemental New Drug Application for MIPLYFFA in infants by Q1 2027.

Q3 sales reach $37.8M as Zevra Therapeutics (ZVRA) swings from loss to profit.

https://www.stocktitan.net/sec-filings/ZVRA/10-q-zevra-therapeutics-inc-quarterly-earnings-report-e5d993e2b5fa.html
Zevra Therapeutics reported a significant financial turnaround in Q3 2026, swinging to a $19.2 million net profit from a $0.5 million loss in the prior year. This was driven by a substantial increase in revenue to $37.8 million, up from $26.1 million, primarily fueled by strong MIPLYFFA product sales. The company also highlighted its full repayment of term loans and a positive operating cash flow of $33.2 million for the first nine months.

Zevra Therapeutics Inc (1GDA.HM) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/1GDA.HM/seasonality/
This Yahoo Finance article provides a seasonal returns chart for Zevra Therapeutics Inc (1GDA.HM). It shows the average monthly price return for the company between 2025 and 2026. The article also notes the upcoming Q3 2026 earnings call scheduled for November 3, 2026.
Advertisement

Zevra Therapeutics Q2 Earnings Call Highlights

https://fr.tradingview.com/news/marketbeat:214c2452f094b:0-zevra-therapeutics-q2-earnings-call-highlights/
Zevra Therapeutics reported strong second-quarter 2026 net revenue of $39.7 million, a 53% increase year-over-year, largely due to U.S. sales of its Niemann-Pick disease type C treatment, MIPLYFFA. The company also detailed efforts to gain European approval for arimoclomol, progress in its celiprolol Phase III trial, and highlighted a solid cash position of $260.2 million.

Earnings Preview: ZVRA to Report Financial Results Post-market on November 03

https://www.moomoo.com/news/post/1002729669/earnings-preview-zvra-to-report-financial-results-post-market-on
This article provides an earnings preview for ZVRA, announcing that the company is scheduled to report its financial results after market close on November 3rd. Investors are advised to watch for this release to understand the company's performance.

Trading Systems Reacting to (ZVRA) Volatility

https://news.stocktradersdaily.com/news_release/17/Trading_Systems_Reacting_to_ZVRA_Volatility_102726061202_1793095922.html
This article from Stock Traders Daily analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report notes elevated downside risk due to a lack of additional long-term support signals.

Zevra Therapeutics, Inc. Estimates – NASDAQ:ZVRA

https://www.tradingview.com/symbols/NASDAQ-ZVRA/financials-estimates/
This article provides an overview of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) financial data and analyst estimates on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Zevra Therapeutics to report Q3FY26 results on November 3

https://scanx.trade/stock-market-news/companies/zevra-therapeutics-report-q3fy26-results-november-3/54042236
Zevra Therapeutics is scheduled to release its third-quarter fiscal year 2026 financial and corporate results on November 3, 2026, after market close, followed by a conference call and audio webcast. The company also recently presented long-term real-world data for its approved Niemann-Pick disease type C (NPC) therapy, MIPLYFFA, at the SSIEM 2026 symposium, demonstrating sustained disease stabilization and a favorable safety profile. These presentations highlighted durable efficacy in both U.S. and German patient populations and detailed the regulatory status, including an ongoing Marketing Authorization Application with the EMA.
Advertisement

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

https://www.globenewswire.com/news-release/2026/10/20/3384268/16626/en/zevra-therapeutics-announces-details-for-q3-2026-financial-results-call.html
Zevra Therapeutics, Inc. announced it will report its third-quarter 2026 corporate and financial results on Tuesday, November 3, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss these results. Details for accessing the webcast and telephone dial-in information have been provided for investors and interested parties.

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

https://www.globenewswire.com/news-release/2026/10/20/3384268/0/en/zevra-therapeutics-announces-details-for-q3-2026-financial-results-call.html
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) announced it will report its Q3 2026 corporate and financial results on Tuesday, November 3, 2026, after market close. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss the results. Details for accessing the webcast and telephone dial-in information are provided.

Form 144 Zevra Therapeutics For: 17 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-zevra-therapeutics-for-17-october-93CH-2741785
The article reports on a Form 144 filing by Zevra Therapeutics for October 17th. It mentions the company's stock symbol ZVRA, which showed a -1.05% change. The content primarily focuses on this financial filing without providing further details.

Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October

https://ng.investing.com/news/stock-market-news/form-4-zevra-therapeutics-inc-neil-f-mcfarlane-director-president-and-ceo-for-10-october-93CH-2735208
This article reports on a Form 4 filing for Zevra Therapeutics Inc., indicating a transaction by Neil F. McFarlane, who holds the titles of Director, President, and CEO. The filing pertains to an event on October 10. The article is a brief financial news item from Investing.com.

Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October

https://ca.investing.com/news/stock-market-news/form-4-zevra-therapeutics-inc-neil-f-mcfarlane-director-president-and-ceo-for-10-october-93CH-4879646
This article reports on a Form 4 filing for Zevra Therapeutics Inc., indicating a transaction by Neil F. McFarlane, who holds the positions of Director, President, and CEO. The filing pertains to an event that occurred on October 10. The article itself was published on October 14, 2026.
Advertisement

Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/zevra-therapeutics-president-and-ceo-sells-224948-in-stock-93CH-4879641
The President and CEO of Zevra Therapeutics (NASDAQ:ZVRA), Neil F. McFarlane, sold 20,000 shares of the company's common stock for a total of $224,948 on October 12, 2026. This sale, executed under a pre-arranged trading plan, followed the acquisition of 50,000 shares through the vesting of restricted stock units. Despite the sale, Zevra Therapeutics recently reported strong Q2 2026 earnings, surpassing analyst expectations, and maintains a "buy" rating from H.C. Wainwright.

A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane.

https://www.stocktitan.net/sec-filings/ZVRA/144-zevra-therapeutics-inc-sec-filing-38d53e550838.html
Zevra Therapeutics (ZVRA) director and officer Neil F. McFarlane reported selling 20,000 common shares on October 12, 2026, for an aggregate market value of $227,800. This sale was reported via a Form 144 filing, which also noted that McFarlane acquired 20,000 common shares as restricted stock units from the issuer on October 10, 2026. The filing indicates that the sale was executed on October 12, 2026, but reported on October 13, 2026, due to a federal holiday.

Zevra Therapeutics, Inc. (ZVRA) options chain

https://uk.finance.yahoo.com/quote/ZVRA/options/?date=1795132800&straddle=false&type=all
This page displays the options chain for Zevra Therapeutics, Inc. (ZVRA), showing real-time price data and basic company stock information. As of the data presented, there are no calls or puts available for the 20 Nov 2026 expiry, with options data delayed by 15 minutes.

Zevra Therapeutics Inc (ZVRA-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/ZVRA/
This article provides stock information and recent news for Zevra Therapeutics Inc. (ZVRA-Q), a rare disease company. It includes real-time stock data, a summary of recent analyst ratings with "Buy" recommendations from various firms, and news releases regarding clinical data publications and patent listings. The company profile highlights its focus on developing transformational therapies for diseases with limited treatment options.

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

https://stocktwits.com/news-articles/markets/equity/zvra-stock-sinks-23-on-eu-setback-analyst-says-risk-is-a-headwind-but-not-insurmountable/cZZpPnzR7zJ
Zevra Therapeutics (ZVRA) shares fell by 23% after the EMA’s CHMP issued a negative opinion on its application to market arimoclomol in Europe for Niemann-Pick disease type C. Despite this, H.C. Wainwright maintained its ‘Buy’ rating and $26 price target, stating that the setback is "not insurmountable" as Zevra plans to request a re-examination. The drug is already approved in the U.S. as MIPLYFFA and generated significant revenue in 2025.
Advertisement

EBIT of Zevra Therapeutics, Inc. – HAN:1GDA

https://www.tradingview.com/symbols/HAN-1GDA/financials-income-statement/ebit/
This article displays the EBIT (Earnings Before Interest and Taxes) for Zevra Therapeutics, Inc. (HAN:1GDA) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily focuses on financial data presentation within the TradingView platform.

Cash per share of Zevra Therapeutics, Inc. – HAN:1GDA

https://www.tradingview.com/symbols/HAN-1GDA/financials-statistics-and-ratios/cash-per-share/
This article provides financial information for Zevra Therapeutics, Inc. (HAN:1GDA) from the Hannover Stock Exchange. It specifically highlights the "Cash per share" value, which is part of the company's financial overview available on the TradingView platform. The content is primarily a data point rather than an in-depth analysis.

Enterprise value to EBIT forward of Zevra Therapeutics, Inc. – HAN:1GDA

https://www.tradingview.com/symbols/HAN-1GDA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/
This article displays the "Enterprise value to EBIT forward" for Zevra Therapeutics, Inc. (1GDA) on the Hannover Stock Exchange. The market was closed at the time of publication, with no trades reported for this specific metric. The content emphasizes financial data and market information for the company.

Total debt per share of Zevra Therapeutics, Inc. – HAN:1GDA

https://www.tradingview.com/symbols/HAN-1GDA/financials-statistics-and-ratios/total-debt-per-share/
This article provides the total debt per share information for Zevra Therapeutics, Inc. (HAN:1GDA) on the TradingView platform. It indicates that the market is closed with no trades recorded and highlights that the data is provided by ICE Data Services and FactSet.

Gross profit of Zevra Therapeutics, Inc. – HAN:1GDA

https://www.tradingview.com/symbols/HAN-1GDA/financials-income-statement/gross-profit/
This article provides the gross profit information for Zevra Therapeutics, Inc. (HAN:1GDA) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The content also notes that the data is provided by ICE Data Services and FactSet.
Advertisement

Three New York conferences will feature Zevra leaders

https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-to-present-at-upcoming-investor-0zzgkrat3jpc.html
Zevra Therapeutics (ZVRA) announced that its executive leadership team will present at three investor conferences in New York in September 2026. These conferences include the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of the fireside chats will be available on Zevra’s investor relations website, and management will also hold one-on-one meetings with registered attendees.

Zevra Therapeutics to Present at Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/09/02/3355014/0/en/zevra-therapeutics-to-present-at-upcoming-investor-conferences.html
Zevra Therapeutics announced that its executive leadership team will present at three upcoming investor conferences in New York, NY: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered attendees. Links to live webcasts will be available on the company's investor relations website.

Zevra Therapeutics to Present at Upcoming Investor Conferences

https://finance.yahoo.com/healthcare/articles/zevra-therapeutics-present-upcoming-investor-113000938.html
Zevra Therapeutics announced that its executive leadership team will present at three upcoming investor conferences in New York: the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Management will also be available for one-on-one meetings with registered attendees. Webcasts of the presentations will be accessible on Zevra's investor relations website.

Zevra Therapeutics to Present New Long-Term Real-World Data

https://www.globenewswire.com/news-release/2026/08/25/3350336/0/en/zevra-therapeutics-to-present-new-long-term-real-world-data-on-miplyffa-in-niemann-pick-disease-type-c-npc-at-the-2026-ssiem-annual-symposium.html
Zevra Therapeutics announced the presentation of new long-term real-world data on MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C (NPC) at the SSIEM Annual Symposium. The data, from U.S. and German early access programs, highlights sustained disease stabilization and a consistent safety profile across diverse NPC patient populations over several years. This reinforces the drug's effectiveness and safety, with some patients experiencing rapid clinical deterioration upon discontinuation.

A rare-disease drug has up to 8 years of real-world data. Zevra will present the findings.

https://www.stocktitan.net/news/ZVRA/zevra-therapeutics-to-present-new-long-term-real-world-data-on-5eqmf3bgwdzy.html
Zevra Therapeutics will present new long-term real-world data on MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium. The data, including up to 8 years of experience from U.S. expanded access and German compassionate use programs, show sustained disease stabilization across various patient populations and ages. MIPLYFFA is FDA-approved in the U.S. and has an EMA Marketing Authorization Application under review, with findings emphasizing its long-term safety and effectiveness in treating NPC.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement